1289646-78-1

Basic information

• Product Name: (S)-benzyl 2-((tert-butoxycarbonyl)amino)-3-((3-methylsulfonyl)phenyl)propionate
• Synonyms: (S)-benzyl 2-((tert-butoxycarbonyl)amino)-3-((3-methylsulfonyl)phenyl)propionate
• CAS NO: 1289646-78-1
• Molecular Weight: 433.525
• Mol File: 1289646-78-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (S)-benzyl 2-((tert-butoxycarbonyl)amino)-3-((3-methylsulfonyl)phenyl)propionate(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-benzyl 2-((tert-butoxycarbonyl)amino)-3-((3-methylsulfonyl)phenyl)propionate(1289646-78-1)
• EPA Substance Registry System: (S)-benzyl 2-((tert-butoxycarbonyl)amino)-3-((3-methylsulfonyl)phenyl)propionate(1289646-78-1)

Safety Data

• Hazardous Substances Data: 1289646-78-1(Hazardous Substances Data)

Usage

General Description

(S)-benzyl 2-((tert-butoxycarbonyl)amino)-3-((3-methylsulfonyl)phenyl)propionate is a chemical compound that belongs to the class of carboxylic acid esters. It is a derivative of the amino acid phenylalanine, with additional groups attached to its structure. The compound contains a benzyl group, a tert-butoxycarbonyl (Boc) protecting group attached to the amino group, and a methylsulfonyl group. This chemical is commonly used in the field of organic chemistry as a building block for the synthesis of various larger molecules and pharmaceuticals. Its specific properties and potential applications may vary depending on the context in which it is used.

Upstream product

• 82278-73-7 (2S)-3-(3-bromophenyl)-2-[(tert-butoxycarbonyl)amino]propanoic acid 
• 1289646-76-9 (S)-2-((tert-butoxycarbonyl)amino)-3-((3-methylsulfonyl)phenyl)propanol 
• 100-51-6 benzyl alcohol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 82311-69-1 (S)-2-amino-3-(3-bromophenyl)propanoic acid 

Downstream Products

• 1194550-59-8 (2S)-2-amino-3-(3-(methanesulfonyl)phenyl)propionic acid benzyl ester hydrochloride 
• 1194550-63-4 C₄₆H₄₀Cl₂N₂O₅S 
• 1194550-65-6 benzyl (S)-2-(5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-[3-(methylsulfonyl)phenyl]propanoate hydrochloride 
• 1194550-67-8 ((S)-benzyl 2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-methylsulfonyl)phenyl)propanoate 
• 1025967-78-5 (S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid 

Relevant articles and documents

Preparation method of lifitegrast intermediate

The invention relates to a preparation method of a lifitegrast intermediate. The preparation method is implemented by the following route, has the advantages of short synthesis route, high yield and high safety, and is simple and convenient to operate and suitable for industrial production. According to the preparation method, a compound II reacts with metal zinc in an organic solvent to generatean organic zinc reagent, a compound I carries out a coupling reaction with the organic zinc reagent, a palladium reagent and a phosphorus ligand to obtain a compound III, and Boc protecting groups ofthe compound III are removed to obtain a compound IV, wherein R1 and R2 groups are respectively and independently selected from methyl, ethyl, vinyl, n-propyl, isopropyl, propenyl, propynyl, cyclopropyl, n-butyl, isobutyl, tert-butyl, butenyl, cyclobutyl, n-pentyl, iso-pentyl, cyclopentyl, n-hexyl, cyclohexyl, phenyl and benzyl.

Discovery and development of potent LFA-1/ICAM-1 antagonist SAR 1118 as an ophthalmic solution for treating dry eye

LFA-1/ICAM-1 interaction is essential in support of inflammatory and specific T-cell regulated immune responses by mediating cell adhesion, leukocyte extravasation, migration, antigen presentation, formation of immunological synapse, and augmentation of T-cell receptor signaling. The increase of ICAM-1 expression levels in conjunctival epithelial cells and acinar cells was observed in animal models and patients diagnosed with dry eye. Therefore, it has been hypothesized that small molecule LFA-1/ICAM-1 antagonists could be an effective topical treatment for dry eye. In this letter, we describe the discovery of a potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonist (SAR 1118) and its development as an ophthalmic solution for treating dry eye.